Abiopharma

🔍 Novoseletsky Anna Rose (Executive)

Company: CANTALOUPE, INC. (CTLP)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Sold 9,466 shares of Common Stock (Direct)
  Date: 2026-05-08 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 19,288 shares of Common Stock (Direct)
  Date: 2026-05-08 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3
• Sold 100,000 shares of Non-Qualified Stock Option (Right to Buy) at $5.19 per share (Derivative)
  Date: 2026-05-08 | Code: D | Expires: 2030-01-24 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4

Footnotes:

• F1: This Form 4 reports securities disposed of under the Agreement and Plan of Merger, dated as of June 15, 2025 (the "Merger Agreement"), by and among Cantaloupe, Inc. (the "Company"), 365 Retail Markets, LLC, Catalyst Holdco I, Inc., Catalyst Holdco II, Inc. and Catalyst MergerSub Inc. ("Merger Subsidiary"), under which Merger Subsidiary was merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger.
• F2: At the effective time of the Merger (the "Effective Time"), each share of common stock of the Company ("Common Stock") reported in this row of this Form 4 was canceled and automatically converted into the right to receive $11.20 in cash, without interest (such amount per share, the "Merger Consideration").
• F3: Each of these restricted stock units of the Company ("RSU") represented a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at or immediately prior to the Effective Time, each RSU that was outstanding immediately prior to the Effective Time was fully vested and free of restrictions and was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration.
• F4: Pursuant to the Merger Agreement, at or immediately prior to the Effective Time, each outstanding option to purchase one share of Common Stock ("Option") having a per share exercise price less than the Merger Consideration ("In-the-Money Option") became fully vested and free of restrictions and was canceled in exchange for cash in an amount equal to (A) the total number of shares of Common Stock for which such In-the-Money Option was exercisable, multiplied by (B) the excess of the Merger Consideration over the per share exercise price of such In-the-Money Option, and each outstanding Company Option having a per share exercise price equal to or greater than the Merger Consideration was canceled without consideration.